Thesis: Superconducting pure-play with a real 108-qubit GA system but tiny revenue (~7M), a thin balance sheet (~48M cash), and a government-contract-dependent model — the dilution-risk lottery ticket among the survivors; watch, high-risk

Verdict: Research-only / watch, not a buy — the highest-risk lottery ticket among the quantum survivors. This is a primary-source pass in a wider quantum-compute deep-dive program. RGTI has a genuine shipped product, but a tiny-revenue income statement, a thin balance sheet that structurally requires dilution, a stock in drawdown, and insiders selling — it fails a trend-hold buy test on every axis at once. No perspective. The house view on quantum stays skeptical-but-watching.

The Story Right Now

Rigetti is the superconducting pure-play in our quantum-computing universe (IONQ, RGTI, QBTS, QUBT, INFQ). Unlike its sibling INFQ, there is no boring revenue-generating business stapled on to fund the moonshot — RGTI is a near-pure pre-commercial quantum-computing bet that funds itself almost entirely through the capital markets. The product is real: Cepheus-1-108Q, the company's first 108-qubit general-availability system, went live in Apr 2026 on AWS Braket and Rigetti's own QCS, at 99.1% median two-qubit and 99.9% median single-qubit gate fidelity. The flagship Ankaa-3 (84 qubits, Dec 2024) hit 99% median iSWAP / 99.5% via fSim, and a 336-qubit Lyra processor targeting "narrow quantum advantage" is expected later in 2026. This is not a slide deck — there is shipped, externally-accessible hardware.

The income statement is the problem. FY2025 revenue was $7.1M — tiny, and roughly flat-to-small relative to a multi-hundred-million-dollar market cap — with Q1'26 revenue of $4.4M. The company lost −$84.7M at the operating line in FY2025 (−$26.0M in Q1'26) and burned −$58.5M of operating cash over the year. Against that $58M/yr burn sits only **$48.1M of cash and equivalents** at Q1'26. That is the thin balance sheet of the survivors: roughly a year of runway on cash alone, which means RGTI structurally funds itself through ATM/equity raises — dilution is not a tail risk here, it is the business model. That is the single most important fact about this stock.

One trap to flag up front, because it will mislead anyone who reads only the net- income line: Q1'26 net income printed +$33.1M — and that is NOT a profit. It is a non-cash, mark-to-market gain on warrants/derivatives, not operating earnings. Strip the accounting noise and the quarter was a −$26.0M operating loss with −$16.2M of cash burned. Anyone presenting RGTI as "GAAP- profitable" is reading a derivative remeasurement as if it were the business. The business loses money every quarter and funds the gap with stock.

The tape says the same thing the fundamentals do: $18.36, down 25.43% over the trailing 30 sessions (range $17.71–$28.06). That is a deep drawdown, not a secular uptrend, and it sits on top of a deeply loss-making, tiny-revenue, insider-sold income statement. A trend-hold approach buys confirmed bottom→pop→flag→breakout trends; RGTI is the opposite of that today. Real hardware milestone, real science, real drawdown — interesting to watch, not a position.

Setup

• Entry zone: watch-only; base above the $17.71 low, reclaim of $24 = first trigger
• Stop: $16
• Target: $28
• Conviction: low (research-only). The rating is about the setup — a stock in a −25% drawdown is pre-confirmation; an entry only exists after a base above $17.71 holds and $24 is reclaimed. Buying here is catching a falling lottery ticket, not trend-holding.

Bull case

• It actually shipped a 108-qubit GA system. Cepheus-1-108Q (Apr 2026) is a real, externally-accessible product on AWS Braket and Rigetti QCS, at 99.1% median two-qubit / 99.9% median single-qubit fidelity — not a roadmap promise. Among pre-commercial quantum names, "you can run a job on it today" is rare.
• Credible superconducting roadmap with a fidelity story. Ankaa-3 (84 qubits, 99% median iSWAP / 99.5% fSim) → 336-qubit Lyra targeting "narrow quantum advantage" in 2026, plus real-time low-latency quantum error correction demonstrated with Riverlane on an Ankaa-class QPU. Error correction is the gate to usefulness, and RGTI is working it on real hardware.
• Government/defense validation. DARPA Quantum Benchmarking Initiative (advanced to Stage A, up to $1M), a $1.5M Air Force Research Lab extension, and a $3.9M DARPA hardware-scalability award. Independent technical due diligence by agencies that don't hand money to vaporware.
• Earnings beat-rate is Bullish (75%). When milestones land, the stock is a high-beta sector-leader on quantum risk appetite — the upside leg is real if a catalyst hits.

Bear case

• Tiny revenue against a speculative multiple. $7.1M FY2025 / $4.4M Q1'26 is effectively pre-commercial; the market cap is pricing fault-tolerant quantum computing that does not yet exist. You are paying a quantum-computing multiple for a research lab's income statement.
• Thin balance sheet → structural dilution is the headline risk. ~$48.1M cash against a ~$58M/yr operating burn is roughly a year of runway on cash alone. RGTI funds itself through ATM/equity raises; every milestone is, in practice, also a financing event. This is the dilution lottery ticket among the survivors — the opposite of INFQ's fortress post-SPAC balance sheet.
• The "profit" is fake. Q1'26's +$33.1M net income is a warrant/derivative mark-to-market gain, not operating earnings (operating line was −$26.0M). FY2025 net was −$216.2M (EPS −$0.70). Anyone underwriting this on headline net income is misreading the business.
• Insiders are selling, hard. 0 buys / 50 sells, net −$73.3M. No insider is putting cash in at these levels; many are taking it out. That is not the signature of a name management thinks is cheap.
• Government-deal dependence is a recurring critique. With almost no commercial product revenue, the growth model leans on DARPA/AFRL-style awards — lumpy, milestone-gated, and exposed to federal budget cycles. A widely-noted knock on the name: "growth model too dependent on government deals."
• The tape fails our test. −25.43% over 30 sessions is a drawdown, not a trend. Leading composite is Neutral (−0.1). Nothing here is a confirmed uptrend to hold.

Catalysts

• Lyra (336 qubits, expected 2026): the "narrow quantum advantage" attempt. A credible demonstration is the single biggest potential re-rating event; a slip or a muted result is the inverse.
• Error-correction progress (Riverlane real-time QEC on Ankaa-class): tangible steps toward fault tolerance are what the multiple is ultimately pricing.
• New government/defense awards (DARPA QBI later stages, AFRL, follow-on hardware-scalability grants): both validation and near-term revenue — but see the bear case on dependence.
• Next earnings: the gate to watch whether revenue inches off the ~$7M base and, critically, the financing cadence — any new ATM/equity raise confirms the dilution thesis and is the thing to watch before this is ever a buy.
• Sector beta: quantum trades as a correlated basket; an IONQ/QBTS catalyst or a sector science milestone (e.g. Google Willow) drags RGTI with it.

Risks

• Dilution is the base case, not a tail. ~$48.1M cash vs ~$58M/yr burn means RGTI must raise within ~a year. Equity raises into a weak tape are dilutive and pressure the stock exactly when the chart is already broken. This is the structural risk that dominates the name.
• Net-income trap (do not misread). The Q1'26 +$33.1M is a non-cash warrant mark-to-market, not operating profit. The operating loss was −$26.0M and cash burn −$16.2M. Always anchor on the operating loss + burn + runway, not the headline net line. (Flagged precisely because it is the easiest way to be wrong about this company.)
• Liquidity-figure trap (resolved here): any short-term-investments XBRL figure for RGTI is stale 2023 data — do not add it to the cash base. Treat ~$48.1M cash & equivalents (Q1'26) as the liquid base. Cite $48.1M.
• Government-revenue concentration. With negligible commercial revenue, a lumpy award schedule and federal budget exposure make the top line both small and unpredictable.
• House skepticism stands. Quantum remains a late-cycle-AI option for our book; a single GA hardware milestone does not overturn that. Real winners, if any, are 1–2yr out.

Financials

All figures code-pulled — SEC XBRL (edgar RGTI --facts, CIK 0001838359), with web-verified milestones; price = Fri 2026-06-26 settled close. No prose math.

Runway: at the $58M/yr operating cash burn (FY2025 −$58.5M; Q1'26 −$16.2M), **$48.1M of cash is roughly a year — short.** Absent a raise, the cash base does not cover a full year of burn, which is why RGTI structurally funds itself through ATM/equity issuance and why dilution is the headline risk, not a footnote. This is the thin-balance-sheet survivor profile — the inverse of INFQ's multi-year post-SPAC fortress. The Q1'26 +$33.1M net income does not change the runway math: it is a non-cash mark, no cash came in the door.

Cross-references

• Watchlist: already in quantum-computing (IONQ/RGTI/QBTS/QUBT/INFQ). Not held. No watchlist mutation — verdict is watch.
• Program: part of a wider quantum-compute deep-dive program (a 10-K per company). This is RGTI's primary-source pass.
• Companions: the 2026-06-28 quantum deep-dive batch — INFQ (the revenue-generating fortress-balance-sheet name), IONQ, QBTS, QUBT. RGTI is the superconducting, thinnest-balance-sheet, highest-risk member of that set.
• Sector science milestone: Google Willow "Quantum Echoes" (Oct 2025) is the headline science marker the whole basket trades against.
• No perspective opened — house view stays skeptical; this pass earns "high-risk, watch," not a thesis.

Sources

• SEC EDGAR — Rigetti Computing, Inc. (CIK 1838359): 10-K filed 2026-03-04 + 10-Q / 8-K filings index
• Rigetti investor news — Cepheus-1-108Q 108-qubit general-availability system (Apr 2026)
• Rigetti investor news — DARPA Quantum Benchmarking Initiative (Stage A), AFRL extension, DARPA hardware-scalability award
• Rigetti investor relations hub (filings, milestones, Ankaa-3 / Lyra roadmap)